EGFR and interstitial lung disease: Multiple studies have reported that the incidence of drug-induced ILD was higher in Japan than in other countries, and this trend was more prominently observed in the postmarketing surveillance studies of the EGFR-TKIs [13–15, 21] and anti-EGFR antibody [20].